



EVIS
PIS ICF v1.4 03 Nov v1.3 17
Jun-2022
Recovered Capacity
(Scotland)
IRAS ID: 307862

## **Participant Information Sheet**

### **Recovered Capacity (Scotland)**

You are invited to consider whether you wish to continue taking part in a research study. To help you decide whether or not to continue, it is important for you to understand why the research is being done and what it will involve. Please take time to read the following information carefully. Talk to others about the study if you wish. Contact us if there is anything that is not clear or if you would like some more information. Take time to decide whether or not you would like to take part.

During your recent admission to hospital you were unable to give consent for entry into the EVIS Trial. We therefore asked your legal representative (welfare attorney, welfare guardian, nearest relative, and independent doctor or an individual appointed by the hospital) who gave consent on your behalf to enter the study. You were entered into the research study by a process approved by the research ethics committee. This is permissible under the Adults with Incapacity Act (Scotland) 2000. Since you have now recovered the ability to make decisions about your care, we are asking your permission to continue your involvement with the study. Before you decide whether or not to continue, it is important for you to understand why the research is being done and what it will involve. Please take time to read the following information carefully. Talk to others about the study if you wish. Contact us if there is anything that is not clear, or if you would like more information. Take time to decide whether or not you wish to continue taking part in the trial.

## **Purpose of the Study**

Sepsis is a life-threatening reaction to an infection. It happens when the immune system overreacts to an infection and starts to damage the body's tissues and organs.

The aim of this research study is to compare the two different ways to treat sepsis, in the early phase of treatment immediately after you arrive in hospital. The standard approach is to give a salt solution fluid through a drip in your arm to start with, then later adding in a medication that increases the blood flow to your vital organs (a vasopressor mediation called norepinephrine) if required. The alternative approach is to start the vasopressor medication immediately, and then later add in extra salt solution fluid via a drip if required. Vasopressors work by increasing the blood pressure which allows a better blood flow to your internal organs. We plan to see which approach is better and to see if they have a role in improving a patient's recovery time, reducing complications, the length of time they stay in hospital and longer term poor health.

Based on research that has already been done, we believe treating patients with vasopressors when they arrive in the Emergency Department, may have potential advantages over the standard fluids used today. However, the evidence is not clear and that is why we are doing this research.

## Why was I invited to take part?

You were admitted to hospital for treatment of infection (sepsis) and your representative agreed that you could join the study. However you are now capable of making an informed decision about whether you wish to continue in the study or not.





EVIS
PIS ICF v1.4 03 Nov v1.3 17
Jun 2022
Recovered Capacitan()
(Scotland)
IRAS ID: 307862

# Do I have to continue to take part?

No, it is up to you to decide whether or not to continue taking part. If you do decide to continue taking part you will be given this information sheet to keep and be asked to sign a consent form. If you decide to take part you are still free to withdraw at any time and without giving a reason. Deciding not to take part or withdrawing from the study will not affect the care you receive or any legal rights.

### What will happen to me if I take part?

A member of the research team will speak to you to discuss your participation in this study and make sure you understand everything. They will explain to you what has already happened to you as part of the study and what we will ask you to do if you choose to continue.

When you were entered into the study you were put at random (like tossing a coin) into one or two treatment groups.

### Treatment 1 – Usual Treatment

You were given the normal treatment used by this hospital for treating infections – a salt solution (balanced crystalloid) solution via a drip. You may have had medication to increase your blood pressure (vasopressors) added at a later point, depending on your condition.

### **Treatment 2 - Intervention**

You were given the medication to increase the blood flow to your vital organs (vasopressors) started immediately, via a drip in your arm. You may have been given extra salt solution fluid through the drip in your arm later, if required.

The medicines used in the intervention arm (norepinephrine) may harm an unborn child and women who are pregnant will not be able to take part in the study. A pregnancy test will be performed before any study treatment is administered in **all** women who could become pregnant. This includes women who routinely use contraception such as the combined oral contraceptive pill, have an intrauterine device (sometimes known as a 'coil') or who abstain from sexual intercourse.

# For Treatment 1 and Treatment 2

Each treatment will be given for as long as they are required, but participation in the trial and collection of data about you will stop at 48 hours. All other treatment will be decided by the doctor treating you, after discussing with you.

Once you leave the hospital we will look at your medical records 30 and 90 days later to see how well you have recovered and if you have been back to hospital for any further tests or treatment. We won't need to contact you again to do this.

Taking part in the study should not cause much inconvenience to you other than having to answer some additional questions about your health and completing a questionnaire. We will contact you to complete a short questionnaire 30 days and 180 days later. The questionnaire takes less than 5 minutes to complete.

You will not need to come to hospital for any additional visits.





EVIS
PIS ICF v1.4 03 Nov v1.3 17
Jun 2022
Recovered Capacity
(Scotland)
IRAS ID: 307862

#### Is there anything I need to do or avoid?

No, there is nothing you need to do or avoid if you continue in this study.

## What are the possible benefits of taking part?

There is no guarantee that you will receive any benefit from this study but the results from this study might help to improve the healthcare of future patients with sepsis.

### What are the possible disadvantages of taking part?

It is not thought that there are many disadvantages to taking part in this study, however as with any treatment there are some risks. Occasionally when patients have vasopressors they develop mild reactions such as a headache or shortness of breath. These reactions normally disappear when the drip is slowed down or stopped. With any intravenous infusion there is also a risk of fluid leaking into the skin, this can cause temporary inflammation and irritation at the surrounding tissue/skin. Evidence suggests that this occurs in about 3% of patients. Your infusion site will be checked regularly by a healthcare professional to prevent any leaking. Another rare side effect of vasopressors is patients may experience an irregular heart rate however you will be closely monitored by the clinical care team to monitor any side effects.

### **Additional Blood Tests**

In some situations, patients within the study will have had extra blood samples taken. The clinician receiving your consent to continue in the study will be able to tell you if this applies to you. Consent to the additional blood samples is optional and there will also be optional consent to give permission for blood samples to be taken for future use.

If this applies to you, the study team have taken three additional blood samples. Each sample is around 15ml (three teaspoons) and is taken in the first 48 hours of the study. Where possible, these blood samples are taken with routine samples to minimise inconvenience/discomfort to you. The blood samples will be analysed for markers of inflammation and immune system function, along with genetic analysis. The blood samples will be shipped to the laboratory in Edinburgh in a coded fashion whereby only the research site will have access to the document that links participant codes with personal identifiable information.

# Will my participation in the study be kept confidential?

Yes. NHS Greater Glasgow & Clyde is the sponsor for this study based in the United Kingdom. We will be using information about you and your medical records in order to undertake this study and will act as the Data Controller for this study. This means that we are responsible for looking after your information and using it properly. NHS Greater Glasgow & Clyde will keep non-identifiable information about you for 20 years after the study has ended.

Your rights to access, change or move your information are limited, as we need to manage your information in specific ways in order for the research to be reliable and accurate. If you withdraw from the study, we will keep the information about you that we have already obtained. To safeguard your rights, we will use minimally personally identifiable information possible.





EVIS
PIS ICF v1.4 03 Nov v1.3 17
Jun 2022
Recovered Capaciand)
IRAS ID: 307862

You can find out more about how we use your information by contacting the Data Protection Team – 0141 355 2059 or email <a href="mailto:data.protection@ggc.scot.nhs.uk">data.protection@ggc.scot.nhs.uk</a>

[NHS/other site] will keep your name, [NHS number] and contact details [add other identifiers] confidential and will not pass any of this information other than a copy of your consent form, which confirms that you agreed to take part in the study. This will only be looked at by an authorised member of the Study Monitoring team.

[NHS/other site] will use this information as needed, to contact you about the research study, and make sure relevant information about the study is recorded for your care, and to oversee the quality of the study. Certain individuals from NHS Greater Glasgow & Clyde and/or regulatory authorities may look at your medical and research records to check the accuracy of the research study. NHS Greater Glasgow & Clyde will only receive information without any identifying information. The people who will analyse the data gathered from this study will not be able to identify you and will not be able to find out your name, [NHS number] or contact details.

[NHS/other site] will keep identifiable information about you from this study for 10 years after the study has finished.

All data gathered during the study will be coded by a unique identified meaning that all of your personal details will be removed. We will record your participation in your medical record so that other doctors involved in your care will be aware. All information obtained for the study will also be entered into a secure computer server which is located at our expert data centre.

If you chose to consent to long term follow up about your future wellbeing by data linkage NHS Greater Glasgow & Clyde will <a href="mailto:share\_provide">share\_provide</a> your personal information (<a href="mailto:NHS/CHI number">NHS/CHI number</a>, postcode, date of birth, sex at birth) to NHS departments (such as NHS digital in England and the electronic Data Research and Innovation Service (eDRIS in Scotland) to NHS departments to allow them to provide information on your health status. We would also like to let you know about other research studies that may be of interest to you and will ask your permission to contact you about them. These studies would be subject to funding and regulatory approvals and your consent for this is optional. If you chose to consent to be contacted about future research studies your personal information will be used by NHS Greater Glasgow & Clyde to facilitate this. Any personal information provided for long term record linkage or contact about future research will be stored securely, kept strictly confidential and processed in accordance with the EU General Data Protection Regulation (GDPR) (2018).

We also ask that we can inform your GP of your participation in the study

# What if there are any problems?

If you have a concern about any aspect of this study please contact a member of the research team (contact details below) who will do their best to answer any questions.

If you have a concern about any aspect of this study, you should ask to speak to your study doctor who will do their best to answer your questions. If you remain unhappy and wish to complain formally you can do this by contacting the chief investigator — Dr Alasdair Corfield Alasdair.corfield@ggc.scot.nhs.uk





EVIS
PIS ICF v1.4 03 Nov v1.3 17
Jun 2022
Recovered Capacitand)
(Scotland)
IRAS ID: 307862

The normal National Health Service Complaints mechanisms are available if you have any concerns or wish to complain. Tel: 0141 201 4500 email: <a href="mailto:complaints@ggc.scot.nhs.uk">complaints@ggc.scot.nhs.uk</a>

In the unlikely event that something goes wrong and you are harmed during the research and this is due to someone's negligence then you may have grounds for legal action for compensation against *[insert health board]* but you may have to pay your legal costs.

## What will happen if I don't want to carry on with the study?

Your participation is entirely voluntary. You can withdraw from the study at any time without giving a reason, without your medical care or legal rights being affected.

If you withdraw from the study, the information which has been collected about you whilst you have been in the study can be used as part of the results of the trial. If you chose to stop participating in the trial we will ask you if you are happy for the data we have collected so far can be used

### What happens when the study is finished?

All the data collected will be kept securely for 10 years after the study has finished in case it needs to be reviewed again. At the end of the study we will make the study data available for other researchers to look at. Before we make it available we will make sure it doesn't contain any data which could be used to identify you.

# What will happen to the results of the study?

This study will be written up and submitted for publication in a medical journal. It is likely that the results will also be presented at academic meetings or conferences. Once the study has been published a summary of the findings will be made available. You will not be identified in any published results. Patients can contact their local study team to find out the final results if they wish.

## Who is organising and funding the research?

The study is sponsored by NHS Greater Glasgow & Clyde and will be coordinated by the Project Management Unit. This study has been funded by the National Institute for Health Research.

## Who has reviewed the study?

The study has been reviewed by an independent group of people called a Research Committee to protect your safety, rights, wellbeing and dignity. A favourable ethical opinion has been obtained by the Scotland A Research Ethics Service. The Medicines and Healthcare Products Regulatory Agency (MHRA) has also reviewed and approved this study.

### **Contact Details**

If you have any further questions about the study please contact the research nurse team on

# [Insert site contact details]

If you would like to discuss this study with someone independent of the study please contact Dr Jamie Scott by email (jamie.cooper2@nhs.scot) or by phone (01224 551817). 

[Insert independen contact details]

Formatted: Font: Not Italic



Participant ID:



EVIS
PIS ICF v1.4 03 Nov v1.3 17
Jun 2022
Recovered Capacity
(Scotland)
IRAS ID: 307862

# Thank you for taking the time to read this information sheet

### **CONSENT FORM**

# **Recovered Capacity (Scotland)**

Principal Investigator: Please Initial box 1. I confirm that I have read and understood the Patient Information Sheet -Recovered Capacity (Scotland) v1.4 03 November 1.3 17 Jun 2022 for the above study. I have had the opportunity to consider the information, ask questions and have had these questions answered satisfactorily. 2. I understand that my participation is voluntary and that I am free to withdraw at any time, without giving any reason and without my medical and/or legal rights being affected. 3. I give permission for the research team to access my medical records for the purposes of this research study. 4. I understand that relevant sections of my medical notes and data collected during the study may be looked at by individuals from the Sponsor (NHS Greater Glasgow & Clyde), from regulatory authorities or from NHS organisations where it is relevant to my taking part in this research. I give permission for these individuals to have access to my data and/or medical records. 5. I agree to my General Practitioner being informed of my participation in this 6. I understand that data collected about me during the study will be converted to anonymised data. 7. I agree to my anonymised data being used in future ethically approved research studies. 8. I agree to take part in the above study.





EVIS
PIS ICF v1.4 03 Nov v1.3 17
Jun-2022
Recovered Capacity
(Scotland)
IRAS ID: 307862

OPTIONAL:			Y	ES	NO
09.	•	es and data I provide can be used ved research in the future, and may er researchers.			
10.	I agree to long term follow-up information by record linkage being collected on my future wellbeing and treatment from NHS and Government Health Records (such as NHS digital in England and the electronic Data Research and Innovation Service (eDRIS in Scotland)-				
11.	I agree to be contacted about studies.	out future ethically approved resea	rch		
12.	I give my permission to give extra samples of blood for research purposes. Lunderstand how these samples were collected, that giving the samples are voluntary and that I am free to withdraw my participation at any time without giving a reason and without my medical care or legal rights being affected.		<del>ring</del>		
13.	l agree to allow long term storage of blood for use in future ethica approved research studies		ally		
<del>14.</del>	l agree to be contacted in the stored blood samples.	future regarding the genetic analysi	<del>s of</del>		
NAME OF PARTICIPANT		SIGNATURE	DATE		
NAME OF INVESTIGATOR/DESIGNEE		SIGNATURE —	DAT	F	





(Scotland) IRAS ID: 307862

When completed: 1 copy for participant; 1 for researcher site file (original) 1 copy to be kept in medical notes. A copy of the consent form should be uploaded to the eCRF.